- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07853599
Diode Laser Versus Conventional Frenectomy in Children
Clinical Outcomes and Local Molecular Biomarker Changes in Gingival Crevicular Fluid Following Diode Laser Versus Conventional Frenectomy in Children: A Randomized Clinical Trial
This prospective, randomized, open-label, parallel-group clinical trial aims to compare diode laser frenectomy with conventional scalpel frenectomy in children aged 8-12 years with a clinical indication for maxillary labial frenectomy. Participants will be randomly allocated in a 1:1 ratio to undergo either diode laser or conventional scalpel frenectomy. Postoperative pain, wound healing, analgesic requirement, feeding difficulty, and daily comfort will be evaluated during follow-up. Gingival crevicular fluid samples will be collected at baseline and on postoperative Days 3, 7, and 14 to assess local molecular changes associated with inflammation, tissue injury, wound healing, and periodontal-alveolar remodeling using RT-qPCR.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
This study is a prospective, randomized, open-label, two-arm, parallel-group clinical trial designed to compare the postoperative clinical and local molecular responses following diode laser and conventional scalpel frenectomy in children.
Children aged 8-12 years with a clinical indication for maxillary labial frenectomy who meet the eligibility criteria will be randomly allocated in a 1:1 ratio to either the diode laser frenectomy group or the conventional scalpel frenectomy group using computer-generated randomization. Because the two surgical procedures are visibly and technically different, masking of the treating clinician and participants is not feasible.
Clinical evaluations will be performed at baseline and during postoperative follow-up. Postoperative pain will be assessed using a 0-10 Visual Analog Scale (VAS), and wound healing will be evaluated using the Landry, Turnbull and Howley Wound Healing Index. Analgesic requirement, feeding difficulty, daily comfort, and other clinical healing findings will also be recorded. Standardized intraoral photographs obtained during follow-up will provide supportive assessment of postoperative wound healing.
Gingival crevicular fluid samples will be collected from the gingival sulcus adjacent to the maxillary central incisors at baseline (Day 0) and on postoperative Days 3, 7, and 14. Two sterile paper points will be used at each sampling time point. Samples will be transferred to RNase-free tubes, transported under cold-chain conditions, and stored at -80°C until molecular analysis.
RNA isolation, complementary DNA synthesis, and RT-qPCR analyses will be performed to evaluate gene expression changes related to inflammation, tissue injury, wound healing, and local periodontal-alveolar remodeling. Planned molecular targets include IL1B, TNF, IL8, FGF2, TGFB1, an LDH metabolism-related target gene, and SOST. GAPDH and ACTB will be used as reference genes. SOST will be evaluated as a secondary exploratory marker of local periodontal-alveolar remodeling.
Changes in clinical and molecular outcomes will be evaluated over time and between treatment groups, including assessment of group, time, and group-by-time effects.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Burçin AVCI, DDS
- Puhelinnumero: +905359558140
- Sähköposti: burcinavci@yyu.edu.tr
Opiskelupaikat
-
-
-
Van, Turkki (Türkiye)
- Van Yüzüncü Yıl University Faculty of Dentistry
-
Ottaa yhteyttä:
- Burçin AVCI, DDS
- Puhelinnumero: +905359558140
- Sähköposti: burcinavci@yyu.edu.tr
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Children aged 8-12 years.
- Presence of a clinical indication for maxillary labial frenectomy.
- Systemically healthy.
- No previous frenulum surgery in the relevant region.
- Ability to attend scheduled clinical follow-up and gingival crevicular fluid sampling visits.
- Written informed consent provided by a parent or legal guardian.
- Age-appropriate assent provided by the child.
- Adequate cooperation to undergo the planned clinical procedures and gingival crevicular fluid sampling.
Exclusion Criteria:
- Presence of a systemic disease or condition that may affect wound healing or inflammatory responses.
- Active local infection or clinically significant inflammation in the relevant region.
- Use of systemic antibiotics, anti-inflammatory drugs, or corticosteroids within the previous month.
- Regular use of medications known to affect wound healing or inflammatory responses.
- Inadequate cooperation preventing completion of the surgical procedure or gingival crevicular fluid sampling.
- Absence of parental/legal guardian consent or child assent.
- Inability to complete the scheduled follow-up and sampling visits.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Diode Laser Frenectomy
Children aged 8-12 years assigned to this arm will undergo maxillary labial frenectomy using a diode laser. Clinical evaluations and gingival crevicular fluid sampling will be performed at baseline (Day 0) and on postoperative Days 3, 7, and 14. |
Maxillary labial frenectomy will be performed using a Woodpecker LX16 Plus diode laser under standardized clinical conditions. The procedure will be carried out by the Department of Periodontology. Laser parameters, including wavelength, power, operating mode, fiber diameter, and application technique, will be standardized according to the final study protocol. |
|
Active Comparator: Conventional Scalpel Frenectomy
Children aged 8-12 years assigned to this arm will undergo maxillary labial frenectomy using a conventional surgical scalpel. Clinical evaluations and gingival crevicular fluid sampling will be performed at baseline (Day 0) and on postoperative Days 3, 7, and 14. |
Maxillary labial frenectomy will be performed using a conventional surgical scalpel under standardized clinical conditions. The procedure will be carried out by the Department of Periodontology according to the study protocol. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Relative IL1B Gene Expression in Gingival Crevicular Fluid
Aikaikkuna: Baseline (Day 0) and postoperative Days 3, 7, and 14
|
Relative IL1B gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated. |
Baseline (Day 0) and postoperative Days 3, 7, and 14
|
|
Relative TNF Gene Expression in Gingival Crevicular Fluid
Aikaikkuna: Baseline (Day 0) and postoperative Days 3, 7, and 14
|
Relative TNF gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated. |
Baseline (Day 0) and postoperative Days 3, 7, and 14
|
|
Relative IL8 Gene Expression in Gingival Crevicular Fluid
Aikaikkuna: Baseline (Day 0) and postoperative Days 3, 7, and 14
|
Relative IL8 gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated. |
Baseline (Day 0) and postoperative Days 3, 7, and 14
|
|
Relative FGF2 Gene Expression in Gingival Crevicular Fluid
Aikaikkuna: Baseline (Day 0) and postoperative Days 3, 7, and 14
|
Relative FGF2 gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated. |
Baseline (Day 0) and postoperative Days 3, 7, and 14
|
|
Relative TGFB1 Gene Expression in Gingival Crevicular Fluid
Aikaikkuna: Baseline (Day 0) and postoperative Days 3, 7, and 14
|
Relative TGFB1 gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated. |
Baseline (Day 0) and postoperative Days 3, 7, and 14
|
|
Relative LDHA Gene Expression in Gingival Crevicular Fluid
Aikaikkuna: Baseline (Day 0) and postoperative Days 3, 7, and 14
|
Relative LDHA gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. Changes over time and differences between the diode laser and conventional scalpel frenectomy groups will be evaluated. |
Baseline (Day 0) and postoperative Days 3, 7, and 14
|
|
Postoperative Wound Healing Assessed Using the Landry, Turnbull and Howley Wound Healing Index
Aikaikkuna: Postoperative Days 3, 7, and 14
|
Postoperative wound healing will be evaluated using the Landry, Turnbull and Howley Wound Healing Index. Healing will be scored from 1 (very poor healing) to 5 (excellent healing). Scores will be compared between treatment groups and across postoperative follow-up time points. |
Postoperative Days 3, 7, and 14
|
|
Postoperative Pain Intensity Assessed Using the Visual Analog Scale
Aikaikkuna: Postoperative Days 3, 7, and 14
|
Postoperative pain intensity will be assessed using a 0-10 Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst imaginable pain. VAS scores will be compared between treatment groups and across postoperative follow-up time points. |
Postoperative Days 3, 7, and 14
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Relative SOST Gene Expression in Gingival Crevicular Fluid
Aikaikkuna: Baseline (Day 0) and postoperative Days 3, 7, and 14
|
Relative SOST gene expression in gingival crevicular fluid will be quantified using RT-qPCR. Expression levels will be normalized using GAPDH and ACTB as reference genes. SOST will be evaluated as an exploratory marker of local periodontal-alveolar remodeling following frenectomy. |
Baseline (Day 0) and postoperative Days 3, 7, and 14
|
|
Postoperative Analgesic Use
Aikaikkuna: Postoperative Days 3, 7, and 14
|
Postoperative analgesic use will be recorded during follow-up. The number of analgesic doses taken by each participant will be documented and compared between the diode laser and conventional scalpel frenectomy groups. |
Postoperative Days 3, 7, and 14
|
|
Postoperative Feeding Difficulty
Aikaikkuna: Postoperative Days 3, 7, and 14
|
Feeding difficulty will be assessed using a 0-10 numerical rating scale, where 0 indicates no difficulty with eating and 10 indicates the greatest possible difficulty. Scores will be compared between the diode laser and conventional scalpel frenectomy groups. |
Postoperative Days 3, 7, and 14
|
|
Postoperative Daily Comfort
Aikaikkuna: Postoperative Days 3, 7, and 14
|
Daily comfort will be assessed using a 0-10 numerical rating scale, where 0 indicates extreme discomfort and 10 indicates complete comfort. Scores will be compared between the diode laser and conventional scalpel frenectomy groups. |
Postoperative Days 3, 7, and 14
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Burçin AVCI, Van Yüzüncü Yıl Universityc
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- VYYU-PEDO-FREN-2026-01
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Individual participant data are not planned to be shared because the study involves pediatric participants and molecular biomarker data. De-identified aggregate results will be reported in scientific publications in accordance with applicable ethical and institutional requirements.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .